Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy

Bone Marrow Transplantation volume 37, pages 929–935 (2006)Cite this article

Abstract

The role of high-dose chemotherapy (HDCT) in patients with refractory breast cancer is not well established. Forty-two female patients (median age of 46 years) with breast cancer refractory to neoadjuvant chemotherapy received HDCT (cyclophosphamide, carmustine and thiotepa) supported by an autologous peripheral blood stem cells transplant. Their disease had been refractory (defined as less than partial response) to one (18 patients) or two (24 patients) regimens of neoadjuvant chemotherapy. Twenty-nine patients had surgery before HDCT. The best response after surgery, HDCT, and radiation therapy was assessed 60 days after transplantation. Thirty patients had complete remission, eight had a PR, one had a minor response, and three had progressive disease. In seven of 13 patients whose disease was inoperable before HDCT, it became operable. After a median follow-up of 42 months, 21 patients were alive, and 15 remained disease free. Five-year overall survival (OS) was 57% (CI, 50–64%), and the estimated 5-year progression-free survival was 40% (CI, 32–48%). Both OS and PFS were better in patients whose disease became operable after chemotherapy than in those whose disease remained inoperable. A randomized study is warranted in this patient population.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93–100.

    Article  CAS  Google Scholar 

  2. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460–469.

    Article  CAS  Google Scholar 

  3. Cristofanilli M, Buzdar AU, Hortobagyi GN . Update on the management of inflammatory breast cancer. Oncologist 2003; 8: 141–148.

    Article  CAS  Google Scholar 

  4. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN . Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 2003; 98: 1150–1160.

    Article  Google Scholar 

  5. Valero V, Buzdar AU, McNeese M, Singletary E, Hortobagyi GN . Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer 2002; 3 (Suppl 2): S63–S68.

    Article  Google Scholar 

  6. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED et al. Breast conservation after neoadjuvant chemotherapy: the M.D. Anderson cancer center experience. J Clin Oncol 2004; 22: 2303–2312.

    Article  Google Scholar 

  7. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165–4174.

    Article  CAS  Google Scholar 

  8. Schwartz GF, Hortobagyi GN, Masood S, Palazzo J, Holland R, Page D et al. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, PA. Hum Pathol 2004; 35: 781–784.

    Article  Google Scholar 

  9. Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU et al. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J 2001; 7: 413–420.

    CAS  PubMed  Google Scholar 

  10. Montemurro F, Rondâon G, Munsell M, Smith TL, Donato ML, Gajewski JL et al. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biol Blood Marrow Transplant 2003; 9: 330–340.

    Article  Google Scholar 

  11. Montemurro F, Rondâon G, Ueno NT, Munsell M, Gajewski JL, Champlin RE . Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. Bone Marrow Transplant 2002; 29: 861–866.

    Article  CAS  Google Scholar 

  12. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast. J Clin Oncol 1997; 15: 3169–3170.

    Article  Google Scholar 

  13. Schwartzberg L, Weaver C, Lewkow L, McAneny B, Zhen B, Birch R et al. High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast. Bone Marrow Transplant 1999; 24: 981–987.

    Article  CAS  Google Scholar 

  14. Viens P, Penault-Llorca F, Jacquemier J, Gravis G, Cowen D, Bertucci F et al. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant 1998; 21: 249–254.

    Article  CAS  Google Scholar 

  15. Adkins D, Brown R, Trinkaus K, Maziarz R, Luedke S, Freytes C et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. J Clin Oncol 1999; 17: 2006–2014.

    Article  CAS  Google Scholar 

  16. Ayash LJ, Elias A, Ibrahim J, Schwartz G, Wheeler C, Reich E et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol 1998; 16: 1000–1007.

    Article  CAS  Google Scholar 

  17. Buchholz TA, Tucker SL, Moore RA, McNeese MD, Strom EA, Jhingrin A et al. Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant. Int J Radiat Oncol Biol Phys 2000; 46: 337–343.

    Article  CAS  Google Scholar 

  18. Wong R, Rondon G, Saliba RM, Shannon VR, Giralt SA, Champlin RE et al. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant 2003; 31: 1157–1163.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Christine Wogan of Department of Scientific Publications at M.D. Anderson Cancer Center for her editorial assistance.

Author information

Authors and Affiliations

  1. Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    N T Ueno, S Konoplev, G Rondón, P Anderlini, S A Giralt, J L Gajewski, M L Donato & R E Champlin

  2. Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    S Konoplev

  3. Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    T A Buchholz

  4. Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    T Smith

  5. Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    M Cristofanilli

Authors
  1. N T Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Konoplev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T A Buchholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Rondón
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Anderlini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S A Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J L Gajewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M L Donato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Cristofanilli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R E Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N T Ueno.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ueno, N., Konoplev, S., Buchholz, T. et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone Marrow Transplant 37, 929–935 (2006). https://doi.org/10.1038/sj.bmt.1705355

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705355

Keywords

Search

Advanced search

Quick links